Biocorrx Inc - BICX STOCK NEWS

BioCorRx Inc. (OTCQB: BICX) announced a 343% revenue increase for 2022, attributed to a higher number of patients treated at licensed clinics and increased membership fees for the UnCraveRx™ program. The CEO highlighted significant progress in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet aimed at treating opioid use disorder, with positive interim safety and pharmacokinetic results. Plans for FDA approval for Expanded Access and fast-track designation are in place. The company reduced operating expenses by nearly 12% while partnering with Government Plus to expand their Beat Addiction Recovery Program for veterans.

BioCorRx announced interim positive results from its Phase I clinical trial of BICX104, an implantable naltrexone pellet, highlighting its safety and effective therapeutic levels lasting 84 days. The study, which included 24 healthy volunteers, showed no serious adverse events, with better adherence (91.6%) compared to Vivitrol (54.5%). Dr. Andrew P. Mallon, the principal investigator, indicated optimism for BICX104's regulatory approval, as BioCorRx is seeking FDA’s expanded access and Fast Track Designation due to the urgency of addressing the opioid crisis affecting over 10 million Americans.

On February 23, 2023, BioCorRx Inc. (OTCQB: BICX) announced the presentation of interim data from its Phase I clinical trial of BICX104, a biodegradable implantable naltrexone pellet aimed at treating opioid use disorder (OUD). Dr. Andrew Mallon reported at the NIH HEAL Initiative Meeting that BICX104 effectively maintains therapeutic levels for up to three months with no serious adverse events observed. Interim safety results indicate good tolerability. The study, funded by the NIH HEAL Initiative, is expected to conclude by the end of March, with final data to follow. The Company anticipates progress towards FDA approval for this innovative treatment option.

BioCorRx Inc. (OTCQB: BICX) is set to present at the Sequire Biotechnology Conference on February 2, 2023, at 2:00 PM ET. CEO Lourdes Felix and President Brady Granier will discuss the company's innovative treatment programs for substance use disorders. The biotechnology sector is predicted to grow to $727 billion by 2025, showcasing the potential of the industry. The Sequire conference will feature numerous biotech companies, offering insights to thousands of investors. BioCorRx focuses on addiction treatment solutions, including the Beat Addiction Recovery program and the UnCraveRx® weight loss initiative. The firm is also developing an FDA-approved implantable naltrexone pellet.

BioCorRx Inc. (OTCQB: BICX) has appointed Mr. Harsha Murthy to its Board of Directors, enhancing its strategic and operational capabilities. Murthy brings extensive experience in pharmaceuticals and finance, currently managing Consummate Capital LLC and previously leading strategic initiatives at King Pharmaceuticals and Eyetech Pharmaceuticals. CEO Lourdes Felix expresses enthusiasm for Murthy's contributions in advancing business development, particularly the potential spin-off of BioCorRx Pharmaceuticals. The company is also focused on the FDA approval of its naltrexone implant, BICX104, aimed at treating addiction disorders.

BioCorRx Inc. (OTCQB: BICX) announced an update on its Phase I clinical trial for BICX104, an implantable biodegradable naltrexone pellet aimed at treating opioid use disorder (OUD). Conducted by BioCorRx Pharmaceuticals, the trial involves healthy volunteers to assess pharmacokinetics and safety. As of now, all participants have completed their treatment phases with no serious adverse events reported. The interim safety data indicates that BICX104 is generally well-tolerated. Full pharmacokinetic data is expected later this month, with a follow-up phase concluding on March 22, 2023. The development of BICX104 is supported by a cooperative agreement with the National Institute on Drug Abuse.

BioCorRx Inc. (OTCQB: BICX) has partnered with Government Plus LLC, enhancing its Beat Addiction Recovery Program for veterans. This collaboration aims to provide innovative treatment solutions for substance abuse and related disorders. Government Plus views BioCorRx as a leader in effective addiction treatments, particularly through the use of naltrexone. Both companies express optimism about the partnership's potential to improve treatment outcomes for veterans, aiming for national expansion of the program.

BioCorRx Inc. (OTCQB: BICX) announced a potential spin-off of its clinical stage subsidiary, BioCorRx Pharmaceuticals, into a separate publicly traded company. The board believes this move could maximize shareholder value by allowing distinct evaluations of both entities. Lourdes Felix, CEO, highlighted the recent advancements in their product, BICX104, an implantable naltrexone pellet targeting opioid use disorder. The spin-off aims to qualify as a tax-free event for shareholders, although no completion timeline is set, and various conditions must be satisfied.

BioCorRx Inc. (OTCQB: BICX) provided a business update for Q3 2022, highlighting the completion of subject enrollment in its Phase I clinical trial for BICX104, a biodegradable naltrexone pellet aimed at treating opioid use disorder. The company expects interim data by year-end. Q3 revenue increased due to more patients treated and a rise in membership fees for the UnCraveRx™ program. Operating expenses were cut by nearly 32%. BioCorRx is also developing BICX104 in collaboration with the National Institute on Drug Abuse, with plans for FDA approval for dual indications.